Oncology Agents Recommendations
To view Article Recommendations, you must have an active subscription.
If your access has expired, you can subscribe at $9.95 per month, the first month of your subscription will be free of charge.
If you think you should be able to access this content, please contact us.
New to F1000? See this week’s top article below for a free preview of a Recommendation.
- » Anti-angiogenic agents
- » Anti-emetics and other drugs combating side effects
- » Cancer gene therapies
- » Cancer vaccines
- » Cytokines
- » Cytoxics
- » Growth factors
- » Hormonal agents
- » Monoclonal antibodies
- » New agents (phase I + II trials) and novel combination therapies
- » Other antineoplastic agents
- » Other supportive care agents
- » Signal transduction inhibitors
This is a large randomized phase III trial; its aim was to show that intermittent androgen deprivation (ADT) was not inferior to continuous ADT in patients with metastatic hormone-sensitive prostate cancer. It failed to demonstrate...
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
2 Recommendations, most recent by
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.